Researchers at the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine have investigated the impact of mesenchymal stem cell exosomes in the treatment of chronic non-healing wounds. These conditions affect 6.5 million people with diabetes and paraplegia in the Unites States alone, at an estimated treatment cost of $25 billion per year.
Researchers at the Cleveland Clinic reported that treating animal subjects with mesenchymal stem cells prevented opioid tolerance despite repeated exposure. Stem cells, when provided after opioid tolerance was established, essentially reversed both tolerance and hypersensitivity to pain associated with opioid tolerance. Although opioids like morphine are essential to the treatment of pain, tolerance requires the use of increasingly higher doses which carry potentially significant morbidity.